Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.83 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29389782 | 1.00 | ADORA3 (0.83) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL19459489 | 0.93 | ADORA3 (0.82) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL24615060 | 0.93 | ADORA3 (0.76) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL7512284 | 0.91 | ADORA3 (0.69) | ADORA3ADORA1 | |
| SCHEMBL19520735 | 0.91 | ADORA3 (0.69) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL937053 | 0.91 | ADORA3 (0.73) | ADORA3ADORA1 | |
| SCHEMBL6493751 | 0.90 | ADORA3 (0.68) | ADORA3ADORA1CYP3A4TSHRNFKB1 | |
| SCHEMBL6211758 | 0.90 | ADORA3 (1.00) | ADORA3ADORA1 | |
| SCHEMBL6211242 | 0.89 | ADORA3 (0.86) | ADORA3ADORA1 | |
| SCHEMBL6491793 | 0.89 | ADORA3 (0.85) | ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9132131-B2 | Use of adenosine A3 receptor agonists for treatment of neuropathic pain | SAINT LOUIS UNIVERSITY (US) | 2015-09-15 | — | — | US | claimed |
| WO-2012145098-A1 | USE OF ADENOSINE A3 RECEPTOR AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN | SAINT LOUIS UNIVERSITY (US) | 2012-10-26 | — | — | WO | claimed |
| US-20120270829-A1 | USE OF ADENOSINE A3 RECEPTOR AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN | SAINT LOUIS UNIVERSITY (US) | 2012-10-25 | — | — | US | claimed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| EP-1241176-A1 | Purine derivatives for the treatment of ischemia | Pfizer Products Inc. (US) | 2002-09-18 | — | — | EP | claimed |
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2025-06-05 | — | — | US | disclosed |
| US-12239654-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4414027-A2 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | Astrocyte Pharmaceuticals, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| WO-2012145098-A1 | USE OF ADENOSINE A3 RECEPTOR AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN | SAINT LOUIS UNIVERSITY (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270829-A1 | USE OF ADENOSINE A3 RECEPTOR AGONISTS FOR TREATMENT OF NEUROPATHIC PAIN | SAINT LOUIS UNIVERSITY (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120134945-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2012-05-31 | — | — | US | disclosed |
| EP-2456419-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | Oradin Pharmaceutical Ltd. (IL) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011010306-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | RAMOT AT TEL-AVIV UNIVERSITY LTD. (IL) | 2011-01-27 | — | — | WO | disclosed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12390483-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885CYP3A4 1414/4885 |
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | ADORA3 4/4885ADORA1 14/4885CYP3A4 1940/4885 |
| US-11839615-B2 | Compounds and methods for treating addiction and related disorders | ADORA2A, TAAR5, ADORA3 | ADORA3 3/4885ADORA1 11/4885CYP3A4 1252/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | ADORA3 29/4885ADORA1 89/4885CYP3A4 2413/4885 |
| US-20250177405-A1 | METHODS OF TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ADORA2A, ADORA3, ADORA1 | ADORA3 2/4885ADORA1 3/4885CYP3A4 2083/4885 |
| US-12239654-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | ADORA3 778/4885ADORA1 994/4885CYP3A4 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.